PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eptacog Alfa→

Eptacog Alfa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
102786-61-8
Molecular formula
Not available
Molecular weight
50000 g/mol
Drug class
Recombinant activated human coagulation factor VIIa (rFVIIabypassing haemostatic agent)
Mechanism of action
Activated factor VII binds tissue factor and activates factor X and, on activated platelet surfaces, factor IX; this supports local thrombin generation and fibrin formation even when factor VIII or IX activity is inhibited or deficient.
Indications / reported uses
  • Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in defined patients with congenital haemophilia and factor VIII/IX inhibitors, acquired haemophilia, congenital factor VII deficiency or Glanzmann thrombasthenia with platelet-transfusion refractoriness; exact eligibility is product-specific

Sources: EMA NovoSeven EPAR · UK SmPC — NovoSeven · EMA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Eptacog Alfa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eptacog Alfa Permitted Daily Exposure (PDE) report (the Eptacog Alfa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eptacog Alfa Occupational Exposure Limit (OEL) report (the Eptacog Alfa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.